[one week gentleman] "purchase with quantity" should put a curse on "sales with gold"? Thousands of drugs have been stopped from trading and restricted from use? Shanghai Nanhai Pharmaceutical Co., Ltd., the controlling shareholder of 2 billion capital increase

With the implementation of the procurement plan with selected information and quantity, "channel is king" and "sales with gold" are dangerous for pharmaceutical enterprises! On November 15, the "4 + 7 urban drug centralized procurement document" was officially released on Shanghai Sunshine pharmaceutical procurement network According to the document, 31 drugs will be purchased in volume in 11 cities including Beijing, Tianjin, Shanghai, Chongqing and Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi'an Compared with the previous 33 varieties, cefazolin / sodium chloride injection and Paclitaxel injection (albumin binding type) are less It is reported that the market share of drugs in 11 cities is about 24.8%, and the annual sales volume of 31 drugs in 11 cities is about 7 billion yuan Although it is not directly promoted to the whole country, as a large-scale procurement after the first appearance of the medical insurance bureau, it is also an extremely important directional action for the development of drug procurement According to a core health care expert, "purchasing with quantity" compresses unreasonable drug circulation links, especially the space for hospitals and doctors to receive kickbacks Those pharmaceutical enterprises that "channel is king" and "bring gold to sell" don't use them On November 13, the first batch of candidate list for volume bargaining was released in Wuhan, and many auxiliary drugs and over 100 million varieties were abandoned Wuhan announced the results of the first round of volume purchasing candidates, and reminded relevant enterprises to do a good job in stock All the shortlisted products are scheduled to implement the new purchase price with volume on December 1, and other products that are not successfully negotiated will be closed Compared with the previously published reference purchase volume of the first batch of bargaining varieties with volume in Wuhan, including 2 catalogues, 48 varieties in total, 36 varieties to be shortlisted and 12 varieties to be abandoned, most of which are auxiliary drugs Only capecitabine and losartan potassium hydrochlorothiazide are abandoned in purchase catalogue I In addition to monosialotetrahexosylganglioside sodium salt, Xueshuantong for injection, danshenchuandomazine, etc were abandoned because of the large price reduction In terms of purchase amount, two over 100 million varieties were abandoned, namely calf serum deproteinization and Xueshuantong for injection In addition, although monosialotetrahexosylganglioside sodium injection has won the bid exclusively, another dosage form of monosialotetrahexosylganglioside sodium salt powder with a purchase amount of more than 100 million has been abandoned Shandong, the 994 drugs are restricted! On November 14, Shandong public resources trading center issued the notice on publicizing the list of products that were not awarded in the centralized purchase of drugs by medical institutions in Shandong Province, which listed 994 product specifications of 501 pharmaceutical enterprises and products that were not awarded in the centralized purchase into the restricted use list According to the notice on further improving the bargaining purchase mechanism and standardizing the online centralized purchase behavior of public medical and health institutions issued by Shandong health and Health Commission, the price and quantity of drugs purchased by public medical and health institutions in the "alternative catalogue" will be monitored and reported regularly In principle, the requirement that the total purchase amount of "restricted use" drugs shall not exceed 5% of the purchase amount of drugs by medical and health institutions remains unchanged Three provinces announced the suspension of online listing of drugs failing to pass the conformity assessment Famous pharmaceutical enterprises such as Beijing New Pharmaceutical Co., Ltd and Sinopharm group were listed on November 15 Guangxi announced the suspension of online trading of drugs failing to pass the conformity assessment, involving four drugs from seven enterprises According to the notice, it is planned to suspend the qualification of the above varieties for online trading in Guangxi from January 1, 2019 Before that, Jiangxi and Heilongjiang have also announced the list of suspension of network hanging without conformity evaluation Jiangxi involves 3 varieties of 2 enterprises, and Heilongjiang has suspended 27 varieties of 24 enterprises, involving many well-known pharmaceutical enterprises such as Zhejiang Jingxin Pharmaceutical Co., Ltd., Sinopharm group, Anhui Baker bio, Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd Shanghai Nanhai Pharmaceutical Co., Ltd is a hot spot among central enterprises On November 16, Hainan Haiyao announced that Xinxing International Pharmaceutical Co., Ltd plans to gain control over Hainan Haiyao by increasing capital in cash, with the amount of capital increase no more than 2 billion yuan It is understood that Xinxing International Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Xinxing International Pharmaceutical Group, which is directly supervised by the SASAC of the State Council According to the agreement disclosed on December 16, the actual controller of Hainan Haiyao has acknowledged that he has made commitments to the future product listing and R & D Progress of Hainan Haiyao: Shanghai lisengte Medical Technology Co., Ltd., which is held by Hainan Haiyao, will complete the registration and listing of the second generation cochlear implant system products by December 31, 2020; China antibody Pharmaceutical Co., Ltd., which is invested by Hainan Haiyao, will By December 31, 2020, at least one new monoclonal antibody class 1 drug product will be approved for listing, and by the end of 2019, China antibody Pharmaceutical Co., Ltd will be listed; Shanghai youcadi Biomedical Technology Co., Ltd., which promises to invest in Hainan Haiyao, will have at least two new chimeric antigen receptor T-cell therapy (car-t) class 1 drug products obtained clinical approval documents by December 31, 2019 In addition, according to the 2018 semi annual report of Hainan Haiyao, the company realized operating revenue of RMB 1.153 billion in the first half of the year, a year-on-year increase of 51.06%; net profit attributable to shareholders of listed companies was RMB 150 million, a year-on-year increase of 31.61% On November 16, Tiantan biology announced that in order to ensure the market supply of blood products, the company plans to invest 1.7 billion yuan to build Yunnan biological products industrialization base project In January this year, Tiantan biology completed the acquisition of Shanghai blood products, Wuhan blood products and Lanzhou Lansheng blood products of Sinopharm Through this series of actions, the business of blood products of Tiantan biology keeps rising According to the first three quarters of 2018 performance express released by Tiantan biology, the company's blood products business realized an operating revenue of 2.057 billion yuan, a year-on-year increase of 51.29%, and a net profit of 560 million yuan, a year-on-year increase of 47.93% Source: Hubei Pharmaceutical Industry Association official account, Beijing News, health point, cypress blue and other declarations: This article only represents the author himself, does not represent the position of Medicine Net, welcome to exchange and supplement in the message area; if necessary, please note the author and source of the article.